Alnylam Pharmaceuticals (ALNY) is drawing fresh attention after being added to the Nasdaq 100, a milestone that tends to pull in index driven demand and sharpen focus on the long term RNAi story. See ...

A technical analysis of Alnylam stock, explaining the recent correction, and what investors should expect next.

Alnylam Pharmaceuticals faces near-term headwinds from TTR franchise momentum concerns. Click here to read why ALNY stock is ...

Massachusetts Institute of Technology professor Phillip Sharp co-founded Alnylam with several others in 2002. It wasn't Sharp ...

Six firms are set to join the Nasdaq 100 Index as part of its annual reconstitution, the benchmark’s overseer said Friday.

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, ...

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were sinking 9.5% lower as of 11:27 a.m. ET on Thursday after falling as much as 12.6% earlier in the day. The sell-off came after the drugmaker ...

Investors in Alnylam Pharmaceuticals, Inc. ALNY need to pay close attention to the stock based on moves in the options market ...

Analyst Ritu Baral of TD Cowen maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), retaining the price target of $282.00. Ritu Baral has given his Buy rating due to a combination of ...

Cantor Fitzgerald analyst Olivia Brayer initiated coverage with a Hold rating on Alnylam Pharma (ALNY – Research Report) yesterday and set a price target of $165.00. The company’s shares closed ...

Lululemon Athletica (LULU) to exit the Nasdaq 100 as part of the gauge's annual shakeup, with Seagate (STX) and five others ...

Amvuttra, an Alnylam drug approved to treat nerve pain from transthyretin amyloidosis, is now FDA-approved for treating cardiomyopathy caused by this disease. The approval brings Amvuttra to a much ...